Ultragenyx Pharmaceutical (RARE) said Monday that it expects 2025 revenue to be in a range of $672 million to $674 million, up 20% compared with 2024.
Analysts surveyed by FactSet expect $656.7 million.
The company said it expects Crysvita, which is used to treat rare bone disorders, will provide revenue of $480 million to $482 million for 2025.
Analysts surveyed by FactSet expect 467.3 million.
Shares of the company were up more than 1% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments